Teduglutide vs Apraglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Gattex, Revestive
Teduglutide is a 33-amino-acid GLP-2 analog approved for short bowel syndrome (SBS) in people who depend on IV nutrition or fluids. GLP-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. The FDA approved it as Gattex in December 2012 (children 1 year and older were added in 2019), and in Europe it is sold as Revestive. It works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement.
Also: FE 203799, Once-weekly GLP-2 analog
Apraglutide is a once-weekly GLP-2 analog for short bowel syndrome, originally from VectivBio and now owned by Ironwood Pharmaceuticals. Its phase 3 STARS trial hit its main goal in 2024, but in April 2025 Ironwood said the FDA wanted a confirmatory trial, partly because patients in STARS got less drug exposure than planned due to how doses were prepared and given. That new trial, STARS-2, started in June 2026, so approval is years away (a submission before end of 2029 has been mentioned).
Key Comparison Insights
- Teduglutide is FDA approved, while Apraglutide remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Teduglutide has stronger research evidence (FDA Approved) compared to Apraglutide (Human Trials).
Detailed Comparison
| Attribute | Teduglutide | Apraglutide |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Teduglutide differs from natural GLP-2 by one amino acid (glycine swapped in at position 2), which shields it from DPP-4 breakdown and stretches its half-life from minutes to roughly 2 hours in healthy people (1.3 hours in SBS). It binds GLP-2 receptors on cells in the intestinal wall, which release local growth factors that increase villus height and crypt depth, improve blood flow to the gut, and slow gastric emptying and secretions. Net result: more absorptive surface and more time to absorb. The same growth signal is the reason for its main safety concern, because it can also speed the growth of polyps or existing tumors in the gut, so the label requires colonoscopy before and during treatment. | Like teduglutide and glepaglutide, apraglutide activates GLP-2 receptors in the gut, signaling the intestinal lining to grow and absorb more. It was engineered for very low clearance and high plasma protein binding, which gives it a much longer half-life. In rat studies its IV half-life was about 159 minutes versus 19 for teduglutide and 16 for glepaglutide, and it kept more gut-growth activity when dosed less often. That is the basis for once-weekly dosing in humans. Same class caveat as the others: long-term stimulation of gut tissue growth carries a theoretical polyp and tumor risk that requires monitoring. |
| Common Dosing | 0.05 mg/kg once daily (labeled dose) Once daily | 2.5-5 mg once weekly by body weight (trial dose) Once weekly |
| Administration | Subcutaneous injection, rotating between abdominal quadrants, thighs, or arms | Subcutaneous injection once weekly |
| Typical Duration | Long-term, with assessment of benefit and ongoing monitoring; IV support is weaned as absorption improves | 24-week primary endpoint, with treatment continued to week 48 and beyond in STARS |
| Best Time to Take | Same time each day, any time of day | Same day each week (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | In the pivotal adult trial (Study 1, NCT00798967), 86 adults with SBS were randomized to teduglutide 0.05 mg/kg daily or placebo for 24 weeks. 63% on teduglutide versus 30% on placebo were responders (at least a 20% cut in weekly IV support at weeks 20 and 24), and weekly IV volume fell 4.4 L versus 2.3 L. In the 2-year open-label extension, 93% of the 30 patients who completed 30 months reached at least a 20% reduction, and a minority came off IV support entirely. An earlier trial (Study 3) used a different primary endpoint that missed at the higher dose, though responder rates at 0.05 mg/kg were 46% versus 6%. A 24-week pediatric study of 59 children aged 1 to 17 led to the 2019 approval: 69% on 0.05 mg/kg cut IV support by at least 20%, and 3 of 26 weaned off. Honest caveats: it is a lifelong therapy for most, benefits fade if stopped, and colon-in-continuity patients often respond less dramatically than those with a stoma. Longer-acting GLP-2 drugs (glepaglutide, apraglutide) are trying to replace the daily shot. | STARS (NCT04627025) randomized 164 adults with SBS and intestinal failure 2:1 to weekly apraglutide (2.5 mg or 5 mg by body weight) or placebo. Topline results in February 2024: weekly parenteral support volume fell 25.5% versus 12.5% on placebo at week 24 (p=0.001). In stoma patients the gap was bigger (25.6% vs 7.8%), and 43% vs 27.5% gained at least one day a week off IV support. But the colon-in-continuity endpoints missed, and enteral autonomy at week 48 (12.5% vs 7.4%) was not significant. Discontinuation for side effects was low (3.6% vs 1.9%). While preparing the NDA, Ironwood found exposure in STARS was lower than intended because of dose preparation and administration, and in April 2025 said the FDA required a confirmatory trial. STARS-2 is a 24-week, placebo-controlled trial of about 124 patients (NCT07742735), started June 2026. So: a positive phase 3 on paper, with a dosing problem that undercuts confidence, and no approval in sight before the end of the decade. |
Frequently Asked Questions: Teduglutide vs Apraglutide
What is the difference between Teduglutide and Apraglutide?
Teduglutide is a healing peptide that teduglutide is a 33-amino-acid glp-2 analog approved for short bowel syndrome (sbs) in people who depend on iv nutrition or fluids. glp-2 is the gut's own growth signal, and teduglutide makes the remaining intestine grow taller villi and absorb more, so some patients can cut back the hours they spend hooked to a drip. the fda approved it as gattex in december 2012 (children 1 year and older were added in 2019), and in europe it is sold as revestive. it works, but it is a serious daily injection with real monitoring requirements, not a gut-health supplement. Apraglutide is a healing peptide that apraglutide is a once-weekly glp-2 analog for short bowel syndrome, originally from vectivbio and now owned by ironwood pharmaceuticals. its phase 3 stars trial hit its main goal in 2024, but in april 2025 ironwood said the fda wanted a confirmatory trial, partly because patients in stars got less drug exposure than planned due to how doses were prepared and given. that new trial, stars-2, started in june 2026, so approval is years away (a submission before end of 2029 has been mentioned). The main differences lie in their mechanisms of action and clinical applications.
Which is better, Teduglutide or Apraglutide?
Neither is universally "better" - the choice depends on your specific goals. Teduglutide is typically used for healing purposes, while Apraglutide is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Teduglutide and Apraglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Teduglutide and Apraglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.